Together these results demonstrate that, in an AML setting with decreased sensitivity to SSI-4 alone, SCD inhibition augments the efficacy of standard AML chemotherapy, likely by enhancing their ability to induce DNA damage. Mouse illustration created with BioRender.com. This evidence concerns the gene SCD and acute myeloid leukemia.